Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 18/20 | 0.66 |
| ▸ | CA1 | P00915 | 18/20 | 0.66 |
| ▸ | CA2 | P00918 | 18/20 | 0.66 |
| ▸ | CA5A | P35218 | 18/20 | 0.66 |
| ▸ | CA9 | Q16790 | 18/20 | 0.66 |
| ▸ | CA5B | Q9Y2D0 | 18/20 | 0.66 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19456805 | 0.93 | CA12 (0.72) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL24767087 | 0.87 | CA12 (0.62) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL22294749 | 0.86 | CA12 (0.72) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL22055974 | 0.86 | CA12 (0.75) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL25893742 | 0.85 | CA12 (0.61) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL25854795 | 0.85 | CA12 (0.61) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL29635265 | 0.84 | CA12 (0.88) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL19456804 | 0.84 | CA12 (0.59) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL29635239 | 0.84 | CA12 (0.66) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL29635247 | 0.83 | CA12 (0.73) | CA12CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115565-A1 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | INNOVATIVE MOLECULES GMBH (DE) | 2025-04-10 | — | — | US | disclosed |
| CN-118556045-A | Solid crystalline forms of a helicase-primase inhibitor and methods of making the same | 创新分子股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4237414-A1 | DEUTERATED AMINOTHIAZOLE COMPOUNDS AS ANTIVIRAL COMPOUNDS | Innovative Molecules GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022090409-A1 | DEUTERATED AMINOTHIAZOLE COMPOUNDS AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115565-A1 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | DNA2, RECQL, BLM | CA12 3081/4885CA1 1807/4885CA2 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.